Management of IgAN

CE / CME

Improving Outcomes in IgAN: Expert Guidance on Evolving Management and Treatment

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: July 01, 2024

Expiration: June 30, 2025

Pietro Canetta
Pietro Canetta, MD, MS

Activity

Progress
1 2
Course Completed

References

  1. Gharavi, AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000;26:354-357.
  2. Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: IgA nephropathy. Am J Kidney Dis. 2015;66:e33-e34.
  3. Magistroni R, D’Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88:974-989.
  4. Kiryluk K, Freedberg DE, Radhakrishnan J, et al. Global incidence of IgA nephropathy by race and ethnicity: a systematic review. Kidney360. 2023;4:1112-1122.
  5. Roberts ISD, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546-556.
  6. Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021;361:176-194.
  7. Saha MK, Julian BA, Novak J, Rizk. Secondary IgA nephropathy. Kidney Int. 2018;94:674-681.
  8. National Institute of Diabetes and Digestive and Kidney Diseases. IgA nephropathy. niddk.nih.gov/health-information/kidney-disease/iga-nephropathy. Accessed June 25, 2024.
  9. Jhaveri KD, Bensink ME, Bunke M, et al. Humanistic and economic burden of IgA nephropathy: systematic literature reviews and narrative synthesis. Pharmacoecon Open. 2023;7:709-722.
  10. KDIGO Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
  11. Kwon CS, Daniele P, Forsythe A, et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy. J Health Econ Outcomes Res. 2021;8:36-45.
  12. Murphy SL, Mahan JD, Troost JP, et al. Longitudinal changes in health-related quality of life in primary glomerular disease: results from the CureGN study. Kidney Int Rep. 2020;5:1679-1689.
  13. Lerma EV, Bensink ME, Thakker KM, et al. Impact of proteinuria and kidney function decline on health care costs and resource utilization in adults with IgA nephropathy in the United States: a retrospective analysis. Kidney Med. 2023;5:100693
  14. Gleeson PJ, O’Shaughnessy MM, Barratt J. IgA nephropathy in adults-treatment standard. Nephrol Dial Transplant. 2023;38:2464-2473.
  15. Suzuki H, Kriyluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795-1803.
  16. Selvaskandan H, Shi S, Twaij S, et al. Monitoring immune responses in IgA nephropathy: biomarkers to guide management. Front Immunol. 2020;11:572754.
  17. Markovitz G. Glomerular disease: updated Oxford classification of IgA nephropathy: a new MEST-C score. Nat Rev Nephrol. 2017;13:385-386.
  18. Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179:942-952. 
  19. International IgAN prediction tool at biopsy—adults. qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults. Accessed June 25, 2024.
  20. Shima Y, Nakanishi K, Yoshikawa N. Non-immunosuppressive therapies for childhood IgA nephropathy. Pediatr Nephrol. 2021;36:3057-3065.
  21. Del Prete D, Gambaro G, Lupo A, et al. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int. 2003;64:149-159.
  22. Remuzzi A, Perico N, Sangalli F, et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol. 1999;276:F457-66.
  23. Chan LYY, Leung JCK, Tang SCW, et al. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol. 2005;16:2306-2317.
  24. Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327:1888-1898.
  25. Coppo R. The gut-renal connection in IgA nephropathy. Semin Nephrol. 2018;38:504-512.
  26. Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402:859-870.
  1. Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev. 2011;91:1-77.
  2. Maguire JJ, Davenport AP. Endothelin receptors and their antagonists. Semin Nephrol. 2015;35:125-136.
  3. Chinook Therapeutics. Atrasentan. chinooktx.com/pipeline/atrasentan. Accessed June 25, 2024.
  4. Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401:1584-1594.
  5. Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023:402:2077-2090.
  6. Dong S, Guo X, Wang H, Sun C. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data. Ther Adv Respir Dis. 2024;18:17534666231223606.
  7. Wheeler DC, Toto RD, Stefansson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100:215-224.
  8. The EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12:51-60.